Continuity of Care and Lifestyle Intervention Programs for Spanish-Speaking Immigrants Without Health Insurance at a Free Clinic in Rhode Island
ORIGINAL RESEARCH — Volume 21 — November 21, 2024
Chilsea Wang, BA1; Jocelyn Yang, BA1; Julia Testa, MA2; Muneet Gill, BS1; Morgan Leonard, MPA2; Anne S. De Groot, MD2,3 (View author affiliations)
Suggested citation for this article: Wang C, Yang J, Testa J, Gill M, Leonard M, De Groot AS. Continuity of Care and Lifestyle Intervention Programs for Spanish-Speaking Immigrants Without Health Insurance at a Free Clinic in Rhode Island. Prev Chronic Dis 2024;21:240136. DOI: http://dx.doi.org/10.5888/pcd21.240136.
PEER REVIEWED
What is already known on this topic?
Lifestyle education programs can improve patient health and decrease use of emergency services, leading to savings for patients and health care systems. However, the effects of destabilizing factors (such as the COVID-19 pandemic) on access to care and health education programs have not been widely studied.
What is added by this report?
This report examines the resilience of a chronic disease management program in an uninsured, low-income Hispanic patient population from 2019 through 2022, during the COVID pandemic.
What are the implications for public health practice?
The results of this report support the implementation of lifestyle change programs to improve health outcomes during times of reduced access to care.
Abstract
Introduction
We conducted a retrospective cohort study to evaluate changes in metabolic biomarkers among participants in Bridging the [Health Equity] Gap (BTG), a free program run by Clínica Esperanza/Hope Clinic (CEHC) for Spanish-speaking immigrants without health insurance in Rhode Island.
Methods
From July 2019 through June 2021, 471 people volunteered to participate in the BTG program. Participants enrolled in lifestyle change classes and visited quarterly with health care providers. We reviewed medical records to collect data on blood glucose, total cholesterol, hemoglobin A1c (HbA1c), and systolic and diastolic blood pressure at baseline and at 6, 12, 18, and 21 months after enrollment. We used paired t tests to identify changes in measurements and conducted a regression analysis to analyze trends in longitudinal patient outcomes.
Results
From baseline to 6-month follow-up, we observed significant decreases in all participants’ mean HbA1c (−0.71%), systolic (−5 mm Hg), and diastolic blood pressure (−2 mm Hg). At 12 months, significant decreases in mean HbA1c persisted among participants with diabetes and prediabetes (−1.07%). At 12 months, participants with mean systolic blood pressure >120 mm Hg also had significant decreases in mean systolic blood pressure (−9 mm Hg), and patients with diastolic blood pressure >80 mm Hg had significant decreases in mean diastolic blood pressure (−9 mm Hg). Local population-level surges in COVID-19 due to Delta and Omicron variants were associated with increases in HbA1c and blood glucose measurements above trendlines.
Conclusion
The BTG program demonstrated resilience in supporting improvement in the metabolic biomarkers of participants, despite disruptions caused by the COVID-19 pandemic, the continued engagement of participants in self-care despite limited health care access, and underscores the positive role of free clinics among low-income, Spanish-speaking immigrants.
Introduction
Inadequate health insurance coverage is a public health challenge in the US (1). Without the negotiation of health insurance providers, health care visits have substantially higher costs (2) and increased population reliance on preventable emergency care (3). Free clinics provide safety-net health care for populations that lack health insurance, some developing innovative health improvement programs or developing workforces that are linguistically and culturally tailored to their patient population (4). However, research is scant on the assessment of health outcomes during stressful periods, such as pandemics, in the population that uses free clinics.
Clínica Esperanza/Hope Clinic (CEHC) is a nonprofit free clinic for adults without health insurance in Providence, Rhode Island. More than 80% of CEHC patients speak primarily Spanish, and a large proportion are first-generation immigrants. CEHC patients face challenges as a result of poor health literacy and chronic health problems. The Bridging the [Health Equity] Gap (BTG) program was initiated at CEHC in 2015 with a mission to reduce health inequities among patients with chronic diseases through continuity of care, goal-setting appointments, and healthy lifestyle interventions. Program participants visit quarterly with CEHC health care providers and enroll in a healthy lifestyle intervention program, either Vida Sana or the National Diabetes Prevention Program (DPP). An evaluation of the financial and clinical effects of the BTG program before the pandemic is available elsewhere (4).
The objective of this study was to describe changes in 5 metabolic biomarkers among participants of the BTG program from July 2019 through July 2022. In this study, the COVID-19 pandemic enabled a natural stress-test of the resilience of the BTG program and improvements in the metabolic biomarkers of program participants. Our hypothesis was that BTG could support continual improvement in the metabolic biomarkers of program participants, despite disruptions caused by the COVID-19 pandemic. We expected to see a significant difference from the alternative (the null hypothesis) that metabolic biomarkers would not improve or change during participants’ enrollment in the BTG program.
Methods
This retrospective cohort study was conducted in March 2024. We reviewed the medical records of 471 patients enrolled in BTG during regular clinical operations at CEHC. The evaluation period began on July 1, 2019, and ended on July 1, 2022.
Participants
From October 1, 2019, through October 31, 2021, community health workers, who explained the nature and purpose of the BTG program, recruited participants from the main clinic of CEHC. Outreach efforts, such as those conducted at the Neighborhood Health Station (an outreach clinic opened during COVID-19), helped eligible participants find the main clinic to seek care and participation in BTG. Eligibility for BTG enrollment at CEHC was extended to all residents in Rhode Island who lacked health insurance and were living with diabetes or prediabetes, hypertension, cardiovascular disease, or overweight or obesity. Previous enrollees in the BTG program could also opt in to the new cohort.
Of the 805 participants enrolled in BTG from January 2016 through June 2019, 22 elected to join the new cohort. All participants signed (or signed again, if they were from the previous cohort) a partnership form giving CEHC permission to record individual data in a de-identified spreadsheet, documenting quarterly and yearly chronic disease assessments. Of 516 people recruited, 471 met enrollment criteria in the BTG program and had sufficient follow-up data (1 baseline measurement and at least 1 follow-up measurement) to be included in this evaluation (Figure 1).
Figure 1.
Flow of participants in the Clínica Esperanza/Hope Clinic Bridging the [Health Equity] Gap program, Providence, Rhode Island, 2019–2022. [A text version of this figure is available.]
Timeline
At enrollment in the BTG program (baseline), we measured the following metabolic biomarkers for each participant: blood glucose, HbA1c, total cholesterol, and systolic and diastolic blood pressure. At the conclusion of each visit, participants scheduled a follow-up appointment for 3 months later. We tracked each participant for a maximum of 8 calendar quarters after their enrollment date. Because the CEHC clinic population is transient as a result of fluctuating employment and documentation status, participants did not always schedule or attend a return visit. We called no-show participants once every calendar quarter until they either scheduled a follow-up or were discontinued from the study. If participants did not have a second set of measurements taken within 2 years after their baseline values, we excluded them from the dataset. We included metrics for all continuing participants in the longitudinal analysis until the date of their last follow-up visit. We determined instructional groups for our lifestyle programs based on start date or entry into the BTG program. We calculated the retention rate as a ratio of the number of participants who attended 1 or more follow-up visits to the total number of participants initially enrolled in the program.
Lifestyle program
A locally developed lifestyle program (Vida Sana) involves classes taught to participants by using culturally attuned, linguistically appropriate materials, with teaching styles meeting the unique needs of participants’ low levels of health literacy (5). The course is taught by CEHC-trained multilingual, multicultural community health workers known as Navegantes (6). A pre-pandemic review of the Vida Sana program found significant improvements in blood pressure during the program (7,8).
CEHC also provides a formal DPP class to BTG participants with prediabetes. The objective of DPP is to reduce the risk of type 2 diabetes through a review of diet and physical activity (9). Participants receive structured, program-specific education on how to achieve and maintain lifestyle changes for 1 year. At CEHC, the course is taught in Spanish by Navegantes, who receive training from the Rhode Island Department of Health (6).
Individualized health coaching sessions in the Vida Sana and DPP formats were provided by Navegantes for patients whose schedules did not allow them to attend group classes or who needed to schedule a makeup class after missing a session of the group class. These sessions were charted as “One-on-Ones,” which were available to patients throughout the analysis period along with recurring cycles of Vida Sana and DPP classes (Figure 2). Participants were also invited to participate in repeated program sessions to maintain lifestyle changes and healthy habits.
Figure 2.
Timeline for the Clínica Esperanza/Hope Clinic Bridging the [Health Equity] Gap program in Providence, Rhode Island, for the evaluation period, July 1, 2019, to July 1, 2022. Names of programs reflect funding sources. Abbreviations: NVS, Navegante Vida Sana; WWVS, Wisewoman Vida Sana. [A tabular version of this figure is available.]
Data collection
This evaluation focused on patients enrolled from July 2019 through July 2021; outcomes were evaluated through July 2022.
Data were collected during normal clinic operations and later accessed for analysis by review of patient medical records. In addition to collecting data on metabolic biomarkers for each participant at baseline and at each subsequent clinic visit, we collected baseline data on participant sex (male or female), age, race and ethnicity, and height and weight. We calculated body mass index (BMI) as weight in kilograms divided by height in meters squared. We used adult BMI categories as specified by the Centers for Disease Control and Prevention: underweight (BMI <18.5), normal weight (BMI 18.5 to <25.0), overweight (BMI 25.0 to <30.0), and obese (BMI ≥30.0) (10).
We defined prediabetes as an HbA1c of 5.7-6.4%, diabetes as HbA1c ≥6.5%, hypertension as systolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥80 mm Hg, and hyperlipidemia as total cholesterol ≥240 mg/dL.
We did not routinely collect data on income or educational level as part of this study; however, CEHC is situated in the Olneyville area of Providence and mostly serves patients from this neighborhood. The annual median family income of the Olneyville neighborhood is estimated at $23,200, based on weighted averages of census tracts and block groups from the 2010 census data and the 2010–2016 American Community Survey (11). In 2024, the federal poverty level for a family of 3 was $25,820, and for a family of 4 was $31,200 (12). CEHC has also been an awardee of the federal Community Development Block Grants program every year since 2015, and reports household income of its patients to the program in furtherance of its mission to help low-income people. Additionally, we surmise that the average educational level of most CEHC clinic patients is below high school level, and some are only able to read with difficulty (unpublished observation of A.D.G.).
The COVID-19 pandemic and clinic operations
COVID-19 presented unique challenges to scheduling follow-up visits and providing the intervention. In the beginning of the pandemic (March 2020), all in-person visits were discontinued to reduce the chances of virus transmission at the clinic. After implementation of transmission prevention measures at the clinic, including previsit COVID-19 antigen testing and the installation of air filters in each examination room, we resumed in-person visits. We set up COVID-19 antigen testing and blood pressure tests at the Neighborhood Health Station to facilitate BTG visits; participants could also participate in Vida Sana or DPP group classes, or have One-on-One sessions with a Navegante at this location.
Class participation was flexible during the pandemic. With masking and testing, participants could attend in person. If participants were unable to attend group classes or when in-person classes were suspended during surges in COVID-19 rates, they could meet with Navegantes by video chat and in person for One-on-One visits to discuss goal setting, nutrition, and chronic disease management. Almost all lifestyle intervention programs, including Vida Sana and One-on-Ones, were conducted online in spring 2020 due to COVID restrictions, with DPP suspended, but by fall 2020, visits were in-person to maintain their effectiveness and attendance. Descriptions of the effect of COVID-19 on the uninsured Spanish-speaking population in Providence and the means by which CEHC provided access to free COVID-19 testing and vaccines for this population are described elsewhere (13,14).
Statistical analysis
We organized participant counts in a symmetrical 4-term elliptical figure (a Venn diagram [15]). The 4 terms were the 4 risk factors: obesity/overweight, hypertension, hyperlipidemia, and diabetes/prediabetes.
We used paired t tests to identify significant changes in blood glucose, HbA1c, cholesterol, and systolic and diastolic blood pressure among participants overall. We also compared measurements that were matched by chronic condition: we examined measurements of HbA1c and blood glucose among participants with prediabetes or diabetes, measurements of total cholesterol among participants with hyperlipidemia, and measurements of blood pressure among participants with hypertension. In addition, we compared baseline measurements between participants with at least 1 follow-up visit and participants who had only baseline measurements. We used the Analysis ToolPak feature in Excel version 16.62 (Microsoft Corp) for initial analysis and later verified with R version 4.4.0 (R Foundation for Statistical Computing), with the help of the packages ggplot2 (16) and OI-biostat (Dave Harrington, OI-biostat Labs; https://github.com/dave-harrington/oi_biostat_labs).
We calculated the mean HbA1c and blood glucose levels of all participants in BTG for each calendar quarter from July 2019 through July 2022, for a total of 12 calendar quarters. Using these calculated means, we performed linear regression in R with the open-source ggplot package and subsequently added 95% CIs. We excluded outliers that resulted from surges caused by COVID-19 variants and used baseline and follow-up measurements in our calculation of means.
In a priori power analysis with G*Power version 3.1.9.7 (Heinrich-Heine-Universität Düsseldorf), the required sample size for significant results from a paired t test was 327 given a 2-sided significance level of .05 and an estimated effect size of 0.2, considered small for behavioral science (17). Two months after recruitment began, a meta-analysis of diabetes self-management education among Latino adults found a pooled effect size of −0.24 (±0.105 at 95% CI) for HbA1c outcomes across 23 studies, validating our conservative estimate of effect size (18). G*Power estimated that the required sample size for an effect size of 0.24 with all other settings unchanged in the paired t test was 227. We conducted a sensitivity analysis with imputation based on a last-observation-carried-forward approach, followed by 2-sample t tests, which found no significant difference in participant outcomes at 6 and 12 months.
Results
During the study period, 45 participants transferred to a traditional health insurance plan or were otherwise lost to follow-up.
Of 471 participants, 211 (44.7%) were women and 260 (55.2%) were men. Most participants self-identified as Hispanic or Latino (91%). The mean (IQR) age was 50 (40–59). Moreover, 52.7% of participants lived with hypertension, 51.8% lived with diabetes or prediabetes, 39.2% lived with hyperlipidemia, and 62.5% lived with overweight or obesity; 69.6% of participants lived with 2 or more of these conditions, and 30.4% of participants lived with 3 or more. For example, 29 (6.1%) had hyperlipidemia, diabetes or prediabetes, obesity or overweight, and hypertension (Figure 3). Overall, the program retention rate was 91%.
Figure 3.
Venn diagram for the distribution of chronic conditions among participants in the Clínica Esperanza/Hope Clinic Bridging the [Health Equity] Gap program in Providence, Rhode Island, for the evaluation period, July 1, 2019, to July 1, 2022. All values are number of participants. [A tabular version of this figure is available.]
Evaluation at 6, 12, 18, and 21 months showed that mean blood glucose levels among participants with diabetes or prediabetes declined between −45.8 and −136.0 points, mean HbA1c among participants with diabetes or prediabetes declined between −0.43 and −1.17 points, and the blood pressure of participants with hypertension declined by −2 to −11 mm Hg (systolic) and −1 to −9 mm Hg (diastolic) (Table).
The evaluation of participant outcomes as a function of their time spent in the BTG program demonstrates improvement at the 1-year mark, with results diminishing after that point. We found significant improvements in metabolic biomarkers at 6 and 12 months, but none at 18-month follow-up and only one at 21-month follow-up (Table). The average HbA1c declined significantly among all BTG participants from baseline to 6 months (from 7.17% to 6.46%; P = .005) and among BTG participants with diabetes or prediabetes at 6 months (8.18% to 7.01%; P < .001) and 12 months (8.10% to 7.03%; P = .002) (Table). In addition, we found a significant decline in blood glucose among participants with diabetes or prediabetes at 6 months, in systolic blood pressure among all participants and participants with hypertension at 6 and 12 months, in diastolic blood pressure among all participants at 6, 12, and 21 months, and among participants with hypertension at 12 months. We also found a significant decline in blood glucose from baseline among all patients who remained in the program at 21 months (n = 14). We found no other significant changes.
In the comparison of participants with at least 1 follow-up visit and participants who had only baseline measurements, participants lost to follow-up did not have significantly different measurements of blood pressure, HbA1c, or blood glucose levels at baseline, but they did tend to have significantly higher total cholesterol levels (Appendix).
In a comparison of mean blood glucose in each calendar quarter in the overall BTG cohort, the trendline had a significantly negative slope (R2 = 0.89) that was, however, interrupted during periods of high rates of COVID-19 transmission (Figure 4). This finding was corroborated by mean HbA1c, which also had a significantly negative slope but had a worse fit, with an adjusted R2 of 0.53 and outliers in the same calendar quarters (Figure 5).
Figure 4.
Mean blood glucose measurements among participants (N = 471) in the Clínica Esperanza/Hope Clinic Bridging the [Health Equity] Gap Program, Providence, Rhode Island, July 2019–July 2022. All visits (baseline and follow-up) were used in calculation of means. The regression excluded outliers found during the Delta (August 2021) and Omicron (January 2022) waves of COVID-19. Shading indicates 95% CIs. [A text version of this figure is available.]
Figure 5.
Mean glycosylated hemoglobin A1c (HbA1c) measurements among participants (N = 471) in the Clínica Esperanza/Hope Clinic Bridging the [Health Equity] Gap Program, Providence, Rhode Island, July 2019–July 2022. All visits (baseline and follow-up) were used in calculation of means. The regression excluded the outlier found during the Omicron (January 2022) wave of COVID-19. Shading indicates 95% CIs. [A text version of this figure is available.]
Discussion
From 2018 through 2022, the percentage of Rhode Island residents without health insurance ranged from 4.8% to 4.9% despite introduction of low-cost health insurance for residents and state expansion of Medicaid (2,19). This statistic obscures racial and ethnic disparities in health insurance coverage. Hispanic residents of Rhode Island are more likely than non-Hispanic residents to lack health insurance, have no regular primary care physician, and experience financial barriers to seeking care (14). The proportion of non-Hispanic White residents without health insurance decreased from 5.2% in 2018 to 1.5% in 2022, while the proportion of Hispanic residents without health insurance was higher overall and decreased from 24.3% to 21.0% during the same period (19,20).
CEHC was established in 2008 to address the need for primary and preventive health care for people without health insurance, with a focus on culturally competent care for all — and the BTG program aligns with this mission. Most BTG participants in our study cohort self-identified as Hispanic or Latino (91%), similar to the 2016–2017 cohort, in which nearly all identified as non-White Hispanic or Latino (4), and in contrast to the general population of Rhode Island, at 17% Hispanic or Latino (21,22). This difference may be due to the location of CEHC in Olneyville, a neighborhood in which 63.9% of the population is Hispanic (23).
Hispanic people are more likely than non-Hispanic White people in Rhode Island to have diabetes, hypertension, and cardiovascular disease. In 2010, the prevalence of diabetes in the state was almost 2 times higher in the Hispanic population (13%) than in the non-Hispanic White population (6.7%) (21). Hypertension, a major contributor to cardiovascular disease, also disproportionately affects Hispanic people compared with non-Hispanic White people (24). Although evidence is conflicting on cardiovascular disease death rates in the Hispanic population relative to the non-Hispanic White population, the rates of nonfatal myocardial infarction and loss of disability-adjusted life years are higher in the Hispanic population than in the non-Hispanic White population in the US (24,25). These trends are not unique to the Hispanic population in the US, with Black, American Indian, Alaska Native, Native Hawaiian, and Pacific Islander populations also facing similar disparities (26). New interventions to prevent complications from poorly managed chronic disease should focus on these groups.
In 2020, rates of primary care and emergency department use decreased across the nation before slowly rising in demand, even above pre-pandemic levels (27,28). Use of the BTG program mirrored this trend, with sharply decreased numbers of office visits in the early pandemic months and subsequent increases. The BTG cohort in this study consisted of 471 patients during the 24-month enrollment window from July 2019 to July 2021, a rate of 19.6 patients per month. This rate is similar to previously published BTG enrollment rates at CEHC’s main clinic in 2018: 805 patients during 41 months (19.6 patients per month) (4). The overall similarity in enrollment rates, despite an initial dip in participation for this study, may have resulted from increased community trust in the BTG program when the clinic began establishing other services, such as free COVID-19 testing, vaccination, and Paxlovid distribution. These services may have raised awareness of CEHC programs.
Participation in BTG activities by women was negatively and disproportionately affected by surges in COVID-19. Overall, 44.7% of BTG participants were women and 55.2% were men. This disproportion may have resulted from increased childcare responsibility caused by closures of childcare facilities and restrictions on children visiting CEHC’s main clinic during the pandemic. Addressing childcare needs may be critical to improving health care access for parents of young children.
Improving access to care for people without health insurance may decrease associated costs imposed on the health care system (29). The potential benefits of BTG participation to the local health system are notable. Our previous study found that BTG participants had 61% fewer potentially preventable emergency department visits, resulting in an average annual potential savings to the Rhode Island health care system of $781,122 (4). Better control of chronic diseases through managing blood glucose, normalizing HbA1c, and reducing blood pressure has been estimated at $1,445 to $2,073 per patient (30).
A survey of low-income Hispanic adults with diabetes at clinics in the Southwest and Midwest found that during the pandemic, many Hispanic adults were unable to receive medical care for diabetes and had an increased frequency of hyperglycemia (31). Barriers to health care during the pandemic, such as job-related pressures, transportation needs, and childcare considerations, also affected BTG participants. No-show rates were high for postbaseline office visits, especially in months where new strains of COVID-19 were emerging in Rhode Island. However, despite this, retention in the program improved significantly to 91%, compared with the previous iteration, where 26.1% were lost to follow-up or transferred to other providers (4). This unexpected result could be attributed to telehealth, which has been shown to increase appointment attendance by reducing barriers related to cost and time, particularly benefiting patients who live far from medical providers (32–34). It is also possible that the current iteration of the program increased its outreach and fostered more timely re-engagement for all CEHC patients as a result of increased funding for vaccinations and COVID-19 testing.
Across metabolic biomarkers, when we compared patient outcomes at different calendar quarters, we found that most significant improvements occurred during the 2019–2020 period (before the COVID-19 pandemic). During the 2020–2021 period (peak COVID-19), biomarkers also improved from baseline, but with a smaller magnitude, reflecting observed decreases in the number of participants and smaller changes in metabolic values, potentially related to disruptions in clinic schedules and patient attitudes toward clinic access. The Delta surge was officially recognized by the state of Rhode Island in August 2021 (35), followed by the Omicron wave, reported by local news organizations in January 2022 (36). These surges coincided with poorer outcomes in blood glucose levels, HbA1c values, and blood pressure control among study participants. Total cholesterol did not change significantly during the evaluation period, possibly because of the known preference of CEHC health care providers to encourage lifestyle changes first, followed by statin medications.
Limitations
Our study has several potential limitations. First, interpretation of the results may be limited because the cohort was not randomized and the BTG program involved voluntary participation (by motivated participants), which precluded an intent-to-treat analysis. Second, we did not collect information about participants’ level of education, which may be a confounder of metabolic outcomes. Third, the data can be generalized only to patients who are willing and able to engage with health education such as that provided by the BTG program, reflecting a potential selection bias such that participants included in this evaluation had the means and will to return for at least 1 follow-up visit. However, sensitivity analysis showed that participants who dropped out appeared to have similar baseline characteristics as those who remained in the study, except for total cholesterol levels, and adding those participants back into data based on their last observation carried forward showed no change in significance. In addition, all BTG participants had a metabolic comorbidity, which does not perfectly reflect real-world populations.
Conclusion
Lack of access to health care contributes to underdiagnosis and undertreatment of chronic diseases and poor continuity of care. Hospitalization of patients without health insurance also has negative financial consequences for patients and health care systems. Innovative programs such as BTG and the associated Vida Sana program, tailored to the cultural and linguistic preferences of their communities, are needed to improve access to care populations that lack health insurance and have low literacy levels. Our results reject the null hypothesis. Despite the disruptions of the COVID-19 pandemic, BTG supported continual improvement in participants’ metabolic biomarkers. Our study illustrates that access to free health care, continuity of care, and lifestyle education programs have positive effects on the health of people who lack health insurance. With our collective efforts, neighborhood by neighborhood, we may yet bridge the gaping divide of health care disparity.
Acknowledgments
We thank the following people for their contributions: CEHC volunteers Pooja Hindocha, Nita J. Nair, Jennifer L. Pigoga, Katie Barry, and Meghan McCarthy, who initiated the BTG program (with Dr De Groot) in 2015; all pandemic-era CEHC staff members and volunteers from 2020 to today, for their steadfast dedication to community health care work in unprecedented times; and all BTG participants, for their perseverance and commitment to learning about lifestyle interventions and working to improve their individual health, while building a local community of health-minded people.
Funding for the BTG program has been provided by Blue Cross & Blue Shield of Rhode Island, the CharterCare Foundation, the Textron Charitable Trust, the Rhode Island Department of Labor and Training, Integra Healthcare, the Rhode Island Department of Health, the US Department of Housing and Urban Development’s Community Development Block Grant program, and the City of Providence. Funding for the DPP at CEHC has been provided by the Rhode Island Department of Health. Funding for the Vida Sana program has been provided by the Rhode Island Department of Health, the Well-Integrated Screening and Evaluation for WOMen Across the Nation (WISEWOMAN) program (funded by the Centers for Disease Control and Prevention), Blue Cross & Blue Shield of Rhode Island, the Textron Charitable Trust, the CharterCare Foundation, and Integra Healthcare.
The authors declared no potential conflicts of interest with respect to the research, authorship, or publication of this article. No copyrighted material, surveys, instruments, or tools were used in the research described in this article.
Author Information
Corresponding Author: Chilsea Wang, BA, 2163 Mornington Ln, San Ramon, CA 94582 (chilseajwang@gmail.com).
Author Affiliations: 1Brown University School of Public Health, Providence, Rhode Island. 2Clinica Esperanza/Hope Clinic, Providence, Rhode Island. 3EpiVax, Inc, Providence, Rhode Island.
References
- Lee EKP, Poon P, Yip BHK, Bo Y, Zhu MT, Yu CP, et al. . Global burden, regional differences, trends, and health consequences of medication nonadherence for hypertension during 2010 to 2020: a meta-analysis involving 27 million patients. J Am Heart Assoc. 2022;11(17):e026582. PubMed doi:10.1161/JAHA.122.026582
- Coughlin TA, Samuel-Jakubos H, Garfield R. Sources of payment for uncompensated care for the uninsured. KFF. April 6, 2021. Accessed March 30, 2024. https://www.kff.org/uninsured/issue-brief/sources-of-payment-for-uncompensated-care-for-the-uninsured
- Powers D, Robinson S, Berchick E, Branham JA, Dalzell L, Dennis L, et al. . Evaluating the Utility of Emergency Department Encounter Data and Examining Social Determinants of Emergency Department Utilization in Utah. 2021. Census Working Papers. US Census Bureau. June 8, 2021. Accessed March 30, 2024. https://www.census.gov/content/dam/Census/library/working-papers/2021/demo/sehsd-wp2021-07.pdf
- Hindocha P, Nair NJ, Pigoga JL, Barry K, McCarthy M, Almeida-Monroe V, et al. . Bridging the [Health Equity] Gap at a free clinic for uninsured residents of Rhode Island. R I Med J (2013). 2018;101(9):27–31. PubMed
- Buckley J, Yekta S, Joseph V, Johnson H, Oliverio S, De Groot AS. Vida Sana: a lifestyle intervention for uninsured, predominantly Spanish-speaking immigrants improves metabolic syndrome indicators. J Community Health. 2015;40(1):116–123. PubMed doi:10.1007/s10900-014-9905-z
- McCarthy M, Barry K, Estrada C, Veliz B, Rosales D, Leonard M, et al. . Recruitment, training, and roles of the bilingual, bicultural Recruitment, training, and roles of the bilingual, bicultural Navegantes: developing a specialized workforce of community health workers to serve a low-income, Spanish-speaking population in Rhode Island. Front Public Health. 2021;9:666566. PubMed doi:10.3389/fpubh.2021.666566
- Risica PM, McCarthy M, Barry K, Oliverio SP, De Groot AS. Community clinic-based lifestyle change for prevention of metabolic syndrome: rationale, design and methods of the ‘Vida Sana/healthy life’ program. Contemp Clin Trials Commun. 2018;12:123–128. PubMed doi:10.1016/j.conctc.2018.10.002
- Risica PM, McCarthy ML, Barry KL, Oliverio SP, Gans KM, De Groot AS. Clinical outcomes of a community clinic-based lifestyle change program for prevention and management of metabolic syndrome: Results of the ‘Vida Sana/Healthy Life’ program. PLoS One. 2021;16(4):e0248473. PubMed doi:10.1371/journal.pone.0248473
- Ratner RE; Diabetes Prevention Program Research. An update on the Diabetes Prevention Program. Endocr Pract. 2006;12(Suppl 1):20–24. PubMed doi:10.4158/EP.12.S1.20
- Centers for Disease Control and Prevention. Adult BMI categories. Updated March 19, 2024. Accessed March 30, 2024. https://www.cdc.gov/bmi/adult-calculator/bmi-categories.html
- Statistical Atlas. Household income in Olneyville, Providence, Rhode Island. No date. Accessed March 30, 2024. https://statisticalatlas.com/neighborhood/Rhode-Island/Providence/Olneyville/Household-Income#figure/household-income-percentiles
- Office of the Assistant Secretary for Planning and Evaluation. Poverty guidelines. 2024. Accessed March 30, 2024. https://aspe.hhs.gov/topics/poverty-economic-mobility/poverty-guidelines
- Barry K, McCarthy M, Melikian G, Almeida-Monroe V, Leonard M, De Groot AS. Responding to COVID-19 in an uninsured Hispanic/Latino community: testing, education and telehealth at a free clinic in Providence. R I Med J (2013). 2020;103(9):41–46. PubMed
- Barry K, Suskin JA, Testa J, Leonard M, De Groot AS. Expanding access to COVID-19 testing, vaccination and treatment at a free clinic for uninsured Spanish-speaking adults in Providence, RI. Hum Vaccin Immunother. 2022;18(6):2144604. PubMed doi:10.1080/21645515.2022.2144604
- Venn J. On the diagrammatic and mechanical representation of propositions and reasonings. Lond Edinb Dublin Philos Mag J Sci. 1880;10(59):1–18.
- Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York; 2016.
- Cohen J. Statistical Power Analysis for the Behavioral Sciences. Taylor & Francis; 2013.
- Hildebrand JA, Billimek J, Lee JA, Sorkin DH, Olshansky EF, Clancy SL, et al. . Effect of diabetes self-management education on glycemic control in Latino adults with type 2 diabetes: a systematic review and meta-analysis. Patient Educ Couns. 2020;103(2):266–275. PubMed doi:10.1016/j.pec.2019.09.009
- State of Rhode Island Department of Health. Healthcare access. 2022. Accessed October 3, 2023. https://health.ri.gov/data/healthcareaccess/
- Wayback Machine. Healthcare access. Rhode Island numbers 2018. Accessed February 10, 2024. https://web.archive.org/web/20191210232246/https://health.ri.gov/data/healthcareaccess
- Kawatu JE, Goldman D, Moy M, Gjelsvik A. Rhode Island Diabetes State Plan 2010–2015. Rhode Island Department of Health; July 2010. Accessed March 10, 2024. https://health.ri.gov/publications/stateplans/2010-2015Diabetes.pdf
- US Census Bureau. QuickFacts Rhode Island. July 1, 2023. Accessed March 10, 2024. https://www.census.gov/quickfacts/fact/table/RI/RHI725222
- Rhode Island Department of Health. Olneyville: Action for a Healthier Community. 2011. Accessed March 10, 2024. https://health.ri.gov/publications/datareports/2011Olneyville.pdf
- Willey JZ, Rodriguez CJ, Moon YP, Paik MC, Di Tullio MR, Homma S, et al. . Coronary death and myocardial infarction among Hispanics in the Northern Manhattan Study: exploring the Hispanic paradox. Ann Epidemiol. 2012;22(5):303–309. PubMed doi:10.1016/j.annepidem.2012.02.014
- McGrath RP, Snih SA, Markides KS, Faul JD, Vincent BM, Hall OT, et al. . The burden of health conditions across race and ethnicity for aging Americans: disability-adjusted life years. Medicine (Baltimore). 2019;98(46):e17964. PubMed doi:10.1097/MD.0000000000017964
- Ndugga N, Hill L, Artiga S. Key data on health and health care by race and ethnicity. KFF. May 21, 2024. Accessed March 30, 2024. https://www.kff.org/key-data-on-health-and-health-care-by-race-and-ethnicity
- Melnick G, O’Leary JF, Zaniello BA, Abrishamian L. COVID-19 driven decline in emergency visits: has it continued, is it permanent, and what does it mean for emergency physicians? Am J Emerg Med. 2022;61:64–67. PubMed doi:10.1016/j.ajem.2022.08.031
- Khalil-Khan A, Khan MA. The impact of COVID-19 on primary care: a scoping review. Cureus. 2023;15(1):e33241. PubMed doi:10.7759/cureus.33241
- Bodenheimer T, Pham HH. Primary care: current problems and proposed solutions. Health Aff (Millwood). 2010;29(5):799–805. PubMed doi:10.1377/hlthaff.2010.0026
- Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, et al. . Quality measure attainment in patients with type 2 diabetes mellitus. Am J Manag Care. 2014;20(1 Suppl):s5–s15. PubMed
- Vickery KD, Novotny PJ, Ford BR, Lantz K, Kavistan S, Singh D, et al. . Experiences of Hispanic safety net clinic patients with diabetes during the COVID-19 pandemic. Sci Diabetes Self Manag Care. 2022;48(2):87–97. PubMed doi:10.1177/26350106221076037
- Bynum AB, Irwin CA, Cranford CO, Denny GS. The impact of telemedicine on patients’ cost savings: some preliminary findings. Telemed J E Health. 2003;9(4):361–367. PubMed doi:10.1089/153056203772744680
- Aras M, Tchang BG, Crawford A, Bledsoe M, Fujioka K, Aronne LJ. Impact of telemedicine during the COVID-19 pandemic on patient attendance. Obesity (Silver Spring). 2021;29(7):1093–1094. PubMed doi:10.1002/oby.23180
- Drerup B, Espenschied J, Wiedemer J, Hamilton L. Reduced no-show rates and sustained patient satisfaction of telehealth during the COVID-19 pandemic. Telemed J E Health. 2021;27(12):1409–1415. PubMed doi:10.1089/tmj.2021.0002
- State of Rhode Island Governor Dan McKee. Executive order 21-86: declaration of disaster emergency for new Covid-19 variants. August 19, 2021. Accessed March 30, 2024. https://governor.ri.gov/executive-orders/executive-order-21-86
- Towne S, Leslie A. RI reports 2,481 new COVID-19 cases, 12 deaths as hospitalizations mount. WPRI. January 18, 2022. Accessed March 30, 2024. https://www.wpri.com/health/coronavirus/january-18-2022-ri-coronavirus-update
Table
Measurement | Months from baseline | No. of participants | Baseline mean (SD) | Follow-up mean (SD) | Difference in means | P valueb |
---|---|---|---|---|---|---|
HbA1c, % | ||||||
All participants | 0 | 386 | 6.58 (2.19) | — | — | — |
6 | 96 | 7.17 (2.71) | 6.46 (1.68) | −0.71 | .005 | |
12 | 56 | 6.61 (2.42) | 6.28 (1.73) | −0.33 | .21 | |
18 | 23 | 6.28 (1.86) | 6.75 (2.12) | 0.47 | .27 | |
21 | 14 | 6.29 (1.65) | 6.02 (0.72) | −0.27 | .38 | |
Participants with diabetes (HbA1c ≥6.5%) or prediabetes (HbA1c 5.7%–6.4%) | 0 | 242 | 7.46 (2.49) | — | — | — |
6 | 55 | 8.18 (2.99) | 7.01 (1.94) | −1.17 | <.001 | |
12 | 26 | 8.10 (2.90) | 7.03 (2.23) | −1.07 | .002 | |
18 | 13 | 7.24 (2.64) | 6.78 (1.80) | −0.46 | .21 | |
21 | 8 | 6.79 (1.82) | 6.36 (0.79) | −0.43 | .44 | |
Blood glucose, mg/dL | ||||||
All participants | 0 | 347 | 139.5 (82.4) | — | — | — |
6 | 92 | 153.3 (102.2) | 139.2 (65.6) | -14.05 | .27 | |
12 | 60 | 150.8 (93.7) | 126.9 (53.2) | -23.93 | .09 | |
18 | 22 | 169.9 (114.9) | 147.4 (97.7) | -22.5 | .49 | |
21 | 14 | 200.4 (143.4) | 107.3 (23.6) | -93.07 | .03 | |
Participants with diabetes (HbA1c ≥6.5%) or prediabetes (HbA1c 5.7%–6.4%) | 0 | 242 | 141 (84) | — | — | — |
6 | 31 | 206 (130) | 160 (77.6) | −45.8 | .02 | |
12 | 12 | 242 (121) | 189 (85.9) | −53.2 | .13 | |
18 | 5 | 308 (125) | 233 (82.3) | −75.0 | .15 | |
21 | 3 | 244 (111) | 108 (22.6) | −136.0 | .12 | |
Total cholesterol, mg/dL | ||||||
Participants with hyperlipidemia (≥240 mg/dL) | 0 | 183 | 237.2 (31.2) | — | — | — |
6 | 34 | 204.6 (47.1) | 204.6 (47.2) | 0 | .99 | |
12 | 25 | 224.7 (54.7) | 221.6 (72.2) | −3.1 | .78 | |
18 | 4 | 204.3 (53.7) | 184.5 (42.5) | −19.8 | .54 | |
21 | 6 | 221.3 (50.9) | 226.3 (29.1) | 5.0 | .82 | |
Systolic blood pressure, mm Hg | ||||||
All participants | 0 | 469 | 133.2 (22.0) | — | — | — |
6 | 118 | 135 (21.3) | 130 (19.9) | −5 | .02 | |
12 | 86 | 134 (22.0) | 129 (15.6) | −5 | .02 | |
18 | 28 | 132 (25.1) | 124 (18.2) | −8 | .11 | |
21 | 17 | 136 (21.4) | 134 (21.6) | −2 | .58 | |
Participants with hypertension (systolic blood pressure >120 mm Hg) | 0 | 246 | 140 (19.0) | — | — | — |
6 | 56 | 144 (19.5) | 137 (17.2) | −7 | .01 | |
12 | 45 | 144 (20.5) | 135 (13.6) | −9 | .006 | |
18 | 15 | 143 (28.2) | 132 (18.6) | −11 | .23 | |
21 | 13 | 142 (21.0) | 140 (21.3) | −2 | .80 | |
Diastolic blood pressure, mm Hg | ||||||
All participants | 0 | 469 | 83 (13.3) | — | — | — |
6 | 118 | 82 (13.0) | 80 (11.6) | −2 | .04 | |
12 | 86 | 83 (12.1) | 79 (9.9) | −4 | .01 | |
18 | 28 | 82 (13.2) | 78 (10.7) | −4 | .16 | |
21 | 17 | 85 (11.4) | 77 (12.5) | −8 | .02 | |
Participants with hypertension (diastolic blood pressure >80 mm Hg) | 0 | 223 | 94 (10.6) | — | — | — |
6 | 13 | 89 (14.7) | 88 (10.3) | −1 | .90 | |
12 | 10 | 88 (6.33) | 79 (7.8) | −9 | .01 | |
18 | 5 | 84 (11.2) | 76 (3.6) | −8 | .28 | |
21 | 6 | 83 (8.0) | 81 (17.1) | −2 | .85 |
Appendix. Supplemental Table
Metabolic indicator | Patients lost to follow-up, mean (SD) | Participants with 1 or more follow-up visits, mean (SD) | P valuea |
---|---|---|---|
Systolic blood pressure, mm Hg | 137.1 (22.3) | 134.5 (22) | .10 |
Diastolic blood pressure, mm Hg | 82.7 (12.9) | 83.7 (13.6) | .20 |
Hemoglobin A1c, % | 6.48 (2.1) | 6.696 (2.3) | .18 |
Blood glucose, mg/dL | 144.0 (87.9) | 136.0 (78.2) | .18 |
Body mass index, kg/m2 | 31.2 (5.3) | 31.6 (5.6) | .18 |
Total cholesterol, mg/dL | 213.0 (5.6) | 202.0 (43.1) | .01 |
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.